NCT04104776 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04104776
Title	A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	endometrial carcinoma lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma germinal center B-cell type ovarian clear cell carcinoma transitional cell carcinoma malignant pleural mesothelioma prostate cancer castration-resistant prostate carcinoma peritoneal mesothelioma Advanced Solid Tumor peripheral T-cell lymphoma
Therapies	Enzalutamide + Tulmimetostat Tulmimetostat
Age Groups:	senior \| adult
Covered Countries	USA \| POL \| ITA \| GBR \| FRA \| ESP

Additional content available in CKB BOOST